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Purpose: The recent Zika virus outbreak was declared a
Public Health Emergency of International Concern by WHO in
February 2016. There is scientiﬁc consensus that Zika virus is a
cause of microcephaly and other congenital anomalies. Cases of
maternal-fetal transmission have been conﬁrmed and congenital
abnormalities associated with maternal Zika virus infection have
been described. In 2015, 1.6million UK residents travelled to South
and Central America and the Caribbean, 28% of these were women
of child bearing age. The risks to and impact on UK travellers to
affected countries is not yet clear. Surveillance studies described
below aim to establish the number of cases and the risk of congen-
ital abnormalities associated with travel to countries with active
Zika virus transmission. Findings may help to describe the typical
features and natural history of this condition, including presen-
tations in relation to time of infection during different stages of
pregnancy as well as long-term outcomes.
Methods & Materials: The UK Obstetric Surveillance system
(UKOSS) conducts surveillance for pregnancy outcomes in moth-
ers with a relevant travel history. Detailed reports are collected
on adverse pregnancy outcomes including miscarriages, stillbirths
and terminations. The British Paediatric Surveillance Unit (BPSU)
records all infants ≤ 6 months of age with microcephaly or neu-
rological abnormalities born in the UK and ROI to mothers who
have travelled to affected countries. Developmental follow-up is
scheduled at 2 years of age. Case ascertainment is facilitated by
conducting both surveillance systems in parallel and ﬁndings will
also be compared to those of the National Congenital Anomaly and
Rare Disease Registration Service (NCARDRS) which collects data
on congenital abnormalities including microcephaly.
Results: Surveillance for congenital Zika syndrome has been
rapidly established in the UK and Republic of Ireland (ROI). UKOSS
surveillance commenced on 1st March 2016, surveillance by BPSU
started on 1st April 2016. To date, no live born case has been iden-
tiﬁed and the number of adverse pregnancy outcomes such as
miscarriages reported has not exceeded expected levels.
Conclusion: Ongoing surveillance of this developing situation
is required to monitor the risks and impact on the UK population
to guide future recommendations and planning for services.
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